Celator’s shares jump on positive late-stage trials for leukaemia drug
pharmafile | March 16, 2016 | News story | Business Services, Research and Development, Sales and Marketing | Celator Pharmaceuticals, EMA, US FDA, Vyxeos, drug trials, phase III
Shares in trial-stage Celator Pharmaceuticals (Nasdaq: CPXX) soared gaining over four times in value as the company announced late-stage trials for its leukemia drug met its primary endpoint.
The company said following the trial results it will file a New Drug Application (NDA) for its drug compound Vyxeos (cytarabine/daunorubicin) with the US Food and Drug Administration (FDA) later in the year and submit a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the first quarter of 2017.
Jeffrey Lancet, the principal investigator for the study, says: “The overall survival advantage seen with CPX-351 compared to 7+3, along with a superior response rate and no increase in serious toxicity indicates that we’ll likely have a new standard of care for treating older patients with secondary AML. This represents a major step forward for a very difficult-to-treat patient population.”
The company said the trials showed Vyxeos significantly improved overall survival in patients with high-risk acute myeloid leukaemia (AML) versus standard of care in a Phase III study.
Dr Gail Roboz, says: “These findings confirm that Vyxeos provides the first opportunity we’ve had in decades to extend survival for patients with high-risk AML. Also, more patients in remission means more who are eligible for potentially curative therapy.”
Shares in the company closed up $7.26 at $8.94, Tuesday on the Nasdaq.
Anjali Shukla
Related Content
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …
AstraZeneca’s Voydeya recommended for approval in EU by CHMP
AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European …
